Convenience and Combination Drugs Sustain Market Growth Even as Heart Failure Risk Looms Large on the Global DPP-IV Inhibitors Market

Epidemic spread of diabetes across the world, convenience of oral medication, and effectiveness of combination drugs despite studies linking risk of heart failures with the use of DPP-4 Inhibitors are poised to drive the global market for DPP-IV Inhibitors to reach US$10.6 billion by the year 2024.

Dipeptidyl Peptidase-IV (DPP4) inhibitors represent an important class of drugs in the treatment of Type 2 Diabetes mellitus. DPP-IV inhibitors, also called “gliptins”, inhibit the DiPeptidyl Peptidase IV (DPP-4) enzyme and enhance the action of its substrate, the incretin hormones, which then aid in increased insulin release and maintain appropriate glucose levels in the blood. Gliptins represent an attractive alternative to the first-line therapy of metformin for diabetes, especially in people who cannot tolerate biguanide metformin hydrochloride because of adverse gastrointestinal effects, and in whom metformin-only therapy is not effective. Sitagliptin (Januvia, Janumet), Vildagliptin (Galvus), Saxagliptin (Onglyza) and others such as Linagliptin, Alogliptin and Teneligliptin are the important drug classes in the DPP-IV inhibitors market.

Nevertheless, despite being well tolerated, most DPP-4 inhibitors are yet to be established with respect to durability of their effects. Certain long-term studies showed that usage of these drugs for over 4 years did not reduce the incidence of athrosclerotic events. This class of drugs may affect cardiac remodelling in patients of established heart failure, and may even increase the risk of new-onset heart failure. This CVD risk, corroborated by the recent FDA’s heart failure warning on the leading drug, Januvia, is likely to hamper the market growth.  However, the increasing demand for DPP-IV combination drugs would help the market to sustain in the ensuing years. Combinations like STEGLUJAN (ertugliflozin and sitagliptin), providing the benefits of both DPP-4 and SGLT-2 inhibitors is expected to result in a balanced therapy with an ideal tolerability and safety profile.

As stated by the new market research report on DPP-IV Inhibitors, the United States represents the largest market. Asia-Pacific ranks as the fastest growing market worldwide, with a CAGR of 9% over the analysis period, due to the huge population of diabetics. The growth in the region is backed by China and India with their huge type-2 diabetic and pre-diabetic population.

Major players in the market include AstraZeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, and Takeda Pharmaceutical Company Limited.

The research report titled "DPP-IV Inhibitors: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, mergers and acquisitions, and other strategic industry activities of major companies worldwide. The report provides market size estimates and projections for geographic markets, such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Russia, and Rest of Europe), Asia-Pacific (China, India, South Korea, and Rest of Asia-Pacific), and Rest of World. Drug compound segments analyzed for the global market include Sitagliptin, Vildagliptin, Saxagliptin, and Others (including Alogliptin and Linagliptin). Drug segments analyzed for the US market include Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin.  

For enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.

For cutting edge analyst reviews on top industries

Follow us on Twitter; Connect with us on LinkedIn; Follow us on Medium